MEKK1 Activation of Human Estrogen Receptor
and Stimulation of the Agonistic Activity of 4-Hydroxytamoxifen in Endometrial and Ovarian Cancer Cells
Heehyoung Lee,
Feng Jiang,
Qiang Wang,
Santo V. Nicosia,
Jianhua Yang,
Bing Su and
Wenlong Bai
Department of Pathology (H.L., F.J., Q.W., S.V.N., W.B.)
University of South Florida College of Medicine and H. Lee Moffitt
Cancer Center Tampa, Florida 33612-4799
Department of
Immunology (J.Y., B.S.) M. D. Anderson Cancer Center
Houston, Texas 77030
 |
ABSTRACT
|
---|
Estrogens are mitogens that stimulate the growth
of both normal and transformed epithelial cells of the female
reproductive system. The effect of estrogens is mediated through the
estrogen receptors, which are ligand-regulated transcription factors.
Tamoxifen, a selective estrogen receptor modulator, functions as an
estrogen receptor antagonist in breast but an agonist in uterus. In the
current study, we show that coexpression of a constitutively active
MEKK1, but not RAF or MEKK2, significantly increases the
transcriptional activity of the receptor in endometrial and ovarian
cancer cells. The expression of wild-type MEKK1 and an active Rac1,
which functions upstream of MEKK1, also increased the activity of the
receptor while coexpression of dominant negative MEKK1 blocked
the Rac1 induction, indicating that endogenous MEKK1 is capable of
activating the receptor. Additional experiments demonstrated that the
MEKK1-induced activation was mediated through both Jun N-terminal
kinases and p38/Hog1 and was independent of the known phosphorylation
sites on the receptor. p38, but not Jun N-terminal kinases,
efficiently phosphorylated the receptor in immunocomplex kinase assays,
suggesting a differential involvement of the two kinases in the
receptor activation. More importantly, the expression of the
constitutively active MEKK1 increased the agonistic activity of
4-hydroxytamoxifen to a level comparable to that of 17ß-estradiol and
fully blocked its antagonistic activity. These findings suggest that
the uterine-specific agonistic activity of the tamoxifen compound
may be determined by the status of kinases acting downstream of MEKK1.
 |
INTRODUCTION
|
---|
Estrogens are pleiotropic hormones that regulate the growth
and differentiation of many diverse tissues. They are also mitogens
that promote the formation and progression of cancers of breast,
endometrium, and ovary, which account for 40% of cancer incidence
among women. The action of estrogens is mediated through the estrogen
receptor (ER), which belongs to the steroid/thyroid nuclear receptor
superfamily, a group of ligand-regulated, zinc finger-containing
transcription factors (1, 2). Two ER genes have been cloned thus far:
the classical ER, which is now designated in the literature as ER
,
and the recently cloned ERß (3, 4, 5). Both ERs contain activation
domains located in the A/B region at the amino terminus and the E
region at the carboxyl terminus, known as activation function 1 and 2
(AF-1 and AF-2), respectively. While AF-1 is active to a certain extent
in the absence of ligands, the activity of AF-2 is highly hormone
dependent. The AFs mediate the transcriptional activation or repression
of target genes independently and/or synergistically in a cell- and
promoter-specific manner (6, 7). So far, the most notable difference
between ER
and ERß is that they are expressed in a
tissue-specific manner. For example, in females, ER
is the
predominant receptor expressed in uterus while ERß is the predominant
type in ovary (8, 9).
In addition to steroids, molecules such as kinase activators,
phosphatase inhibitors, neurotransmitters, cell cycle regulators, and
growth factors also regulate the activity of steroid receptors
including ERs (10, 11, 12). The non-ligand-induced ER activation has
profound clinical implications. First, it may contribute to the
hormone-independent growth of human cancers. Second, it may contribute
to the tissue-specific agonistic activity of synthetic antiestrogens
such as tamoxifen, the prototype of selective ER modulators (SERMs).
Furthermore, the physiological relevance of the non-ligand-induced ER
activation has been demonstrated in whole animal experiments. For
example, epidermal growth factor (EGF) and insulin-like growth factor I
(IGF-I) increase progesterone receptor synthesis in fetal uterus and
antiestrogens block this effect (13, 14, 15). In the mouse uterus, EGF
promotes growth, increases lactoferrin production, and induces
biochemical changes of ERs such as increased DNA binding and production
of heterogenous forms of the receptor (11, 16). These effects of EGF,
which mimic those of estrogens, do not occur in ER
-deficient mice
and thus are ER
mediated (17). Other studies suggest that ER
activation by EGF in COS1 (18) and Hela (19) cells is mediated through
the direct phosphorylation of Ser118 in the AF-1
region by the external signal-regulated kinases (ERKs), which are the
prototype of mitogen-activated protein kinases (MAPKs).
The MAPK family includes not only the ERKs but also the more
recently identified c-Jun N-terminal kinases (JNKs), also referred as
stress-activated protein kinases (SAPKs) and p38/Hog-1. MAPKs are
phosphorylated and activated by MAPK kinases (MAPKKs; e.g.
MEKs and JNKKs), which in turn are phosphorylated and activated by MAPK
kinase kinases (MAPKKKs; e.g. RAF, Mos, and MEKKs). Whereas
RAF and Mos primarily activate the ERKs, MEKKs are known to
preferentially regulate JNK pathways.
To assess the involvement of the different MAPK pathways in ER
activation, we examined the transcriptional activity of ER
in
endometrial and ovarian cancer cells transfected with constitutively
active forms of three different MAPKKKs, MEKK1, MEKK2, and RAF. Our
studies demonstrated that the transcriptional activity of the ER
was
enhanced by the expression of full-length or constitutively active
MEKK1 but not by its relatives, MEKK2 or RAF. We also found that
MEKK1-induced ER
activation was mediated through both JNK and p38
and that MEKK1 activation fully blocked the antagonistic activity of
4-hydroxytamoxifen, a metabolite of tamoxifen that is a well
established estrogenic mitogen for endometrial cancers.
 |
RESULTS
|
---|
MEKK1 Increased the Transcriptional Activity of Human ER
in
Endometrial Cancer Cells
Ishikawa cells are derived from tissues naturally targeted by
estrogens and, for this reason, were used in our studies examining the
role of MAPKs in the transcriptional activation of ER
. Because
Ishikawa cells are heterogeneous with respect to endogenous ER
expression (20), we first assessed the effect of endogenous as well as
transfected ER
on the activity of an ER reporter gene, EREe1bCAT, in
which synthetic estrogen response elements were placed in front of the
simple promoter of adenovirus E1b gene and chloramphenicol acetyl
transferase (CAT). As shown in Fig. 1A
, 17ß-estradiol did not activate the ER reporter gene in the absence of
the ER
expression vector. In contrast, when the cells were
cotransfected with the ER
expression vector and treated with
17ß-estradiol, reporter activity increased about 5 fold. Ectopic
ER
expression had little effect on reporter activity in the absence
of 17ß-estradiol. These findings demonstrate that endogenous ER, if
present, lacks detectable transcriptional activity. However, the
transcriptional machinery required for estrogen-induced ER activation
is intact in these cells.

View larger version (24K):
[in this window]
[in a new window]
|
Figure 1. Enhancement of ER activity by
Constitutively Active MEKK1 in Endometrial Cancer Cells
A, Ishikawa cells were transfected with 0.5 µg EREe1bCAT and 0.5 µg
pLENßgal with or without 0.1 µg pLEN-hER and treated with or
without 10-10 M 17ß-estradiol
(E2) as described in Materials and
Methods. CAT activity was determined and normalized to ß-gal
activity. B, Cells were transfected with the same constructs as in
panel A but together with 0.2 µg of SR MEKK1(CT), SR HAMEKK2(CT),
SR RAF(BxB) or parental vector SR 3. After treatment with
indicated concentrations of 17ß-estradiol, CAT activity was
determined, and normalized activity is expressed as fold activation
relative to SR 3 activity in the presence of
10-10 M 17ß-estradiol.
C, Cells were transfected with the same constructs as in panel A and
0.2 µg of SR MEKK1(CT) or SR 3. Transfected cells were treated
with or without 10-9 M
17ß-estradiol and 10-7 M
ICI 182,780 (ICI) as indicated. CAT activity is expressed as in panel
B. D, Cells were transfected with 0.5 µg EREe1bCAT or EREtkCAT, 0.5
µg pLENßgal, 0.1 µg pLEN-hER , and 0.2 µg of SR 3 or
SR MEKK1(CT). Transfected cells were treated with
10-8 M 17ß-estradiol,
and CAT activity is expressed as in panel B. E, Immunodetection of
human ER from lysates of MCF-7 (positive control) or Ishikawa cells
transfected with SR 3, SR MEKK1(CT), SR HAMEKK2(CT), or
SR RAF(BxB) and with or without pLEN-hER . Transfected cells were
treated with (+E2) or without
(-E2) 10-8
M 17ß-estradiol. Duplicated samples from the
transfected cells were analyzed and shown.
|
|
The negligible transcriptional activity of endogenous ERs allowed us to
examine the effect of different MAPKKKs on the activity of
exogenously expressed ER
in Ishikawa cells. As determined by
reporter gene assays, the ER
activity induced by
10-10 M 17ß-estradiol was further
enhanced by coexpression of constitutively active MEKK1, but not by
active MEKK2 or RAF (Fig. 1B
). The extent of enhancement was comparable
to that caused by a 100-fold increase in estrogen concentration, and
thus apparently is significant. MEKK1 did not activate the reporter
gene in the absence of exogenous ER
expression, confirming that
activation of the reporter gene by MEKK1 is ER
-dependent. This
conclusion is consistent with the capacity of ER antagonist ICI 182,780
to block the MEKK1 activation (Fig. 1C
) and the promoter independency
of the activation, which was similarly observed on both EREe1bCAT and
EREtkCAT (Fig. 1D
). EREtkCAT is a more complex ER reporter in which
CAT expression is controlled by synthetic estrogen response elements
linked to a portion of thymidine kinase (tk) promoter which, in
contrast to E1b promoter, contains binding sites for multiple
sequence-specific transcription factors.
As determined by Western blotting, expression of active MEKK2 or RAF
increased ER
levels in the absence of estrogen, and estrogen
treatment decreased the ER
level as expected (Fig. 1E
). However,
constitutive active MEKK1 did not increase ER
expression in either
the absence or presence of estrogen, indicating that the increase in
ER
activity induced by MEKK1 was not due to increased expression of
the transfected ER
. In the presence of estrogen, the ER
level in
MEKK1-transfected cells is much lower than the level in cells
transfected with control vector. Since it is known that ER activation
is associated with increased ER degradation (21), the data further
indicate that MEKK1 activated ER
. Consistent with transcriptional
data in Fig. 1A
, little endogenous ER
protein was detected in cells
transfected with SR
3 but without ER
expression vector and treated
with or without estrogen (Fig. 1E
). The ER
antibody detected ER
in MCF-7 cells but did not detect any signal at the predicted size in
ER-negative COS cells (data not shown). These findings indicate that
this antibody is ER
-specific.
To determine dosage effects of the different MAPKKKs on ER
activation, various amounts of active MEKK1, MEKK2, and RAF were
cotransfected with the ER
expression plasmid and EREe1bCAT reporter
into Ishikawa cells, and the cultures were treated with
10-8 M 17ß-estradiol. For
comparative purposes, replicate cultures were transfected with similar
amounts of the MAPKKKs and an AP1 reporter, AP-1-CAT, to determine the
effect of the MAPKKKs on endogenous AP1. As shown in Fig. 2A
, MEKK1 activated ER
at all three
tested dosages, but the activation was highest at an intermediate dose
of 0.2 µg DNA. A similar profile was observed for AP1 activity (Fig. 2B
), suggesting that MEKK1 at 1 µg may result in a level of MEKK1
expression that is toxic to the cell. Although neither MEKK2 nor RAF
activated ER
at any of the dosages examined, these kinases activated
AP1 as effectively as did MEKK1. The finding indicates that the lack of
ER
activation by MEKK2 or RAF was not due to lower kinase activity
or level of protein expression in the transfected cells.

View larger version (30K):
[in this window]
[in a new window]
|
Figure 2. Correlation of MEKK1-Induced ER Activation with
MEKK1-Induced Activation of Endogenous AP1
A, Ishikawa cells were transfected with 0.5 µg EREe1bCAT, 0.5
µg pLENßgal, 0.1 µg pLEN-hER , and the indicated amounts of
SR MEKK1(CT), SR HAMEKK2(CT), SR RAF(BxB), or SR 3.
Transfected cells were treated with 10-8
M 17ß-estradiol. B, Ishikawa cells were transfected
with 0.2 µg AP-1-CAT, 0.5 µg pLENßgal, and indicated amounts of
SR MEKK1(CT), SR HAMEKK2(CT), SR RAF(BxB), or SR 3; CAT
activity was determined, and normalized activity is expressed as fold
activation relative to SR 3 activity. The total amount of DNA used in
transfections was equalized with SR 3.
|
|
The constitutively active MEKK1 is a truncated form of
full-length MEKK1. To eliminate the possibility that the increased
ER
activation by the active MEKK1 was due to artifacts resulting
from truncation of the kinase, the effect of full-length MEKK1 on ER
activity was examined. As shown in Fig. 3A
, the full-length MEKK1 activated the
ER in a dose- dependent manner, albeit to a lesser extent than did
active MEKK1 (compare with Figs. 1B
and 2A
). This is not surprising
because full-length MEKK1 in its basal state is less active and depends
on upstream activators such as Rac1 to induce its activity to a higher
level.
To determine whether endogenous MEKK1 was capable of mediating ER
activation in response to signals upstream of MEKK1, the effect of Rac1
on the ER activity was examined. As shown in Fig. 3B
, expression of
active Rac1 efficiently activated ER
. Cotransfection of a dominant
negative MEKK1 inhibited the effect of Rac1 in a dose-dependent manner,
thus indicating that Rac1 enhanced ER
activity via activation of
endogenous MEKK1. As a negative control, we also show that a dominant
negative MEKK2 did not affect the Rac1-mediated ER
activation.
Activation of ER
by MEKK1 Was Mediated through JNK and p38
To elucidate the mechanism of ER
activation by MEKK1, the
involvement of MAPKKs downstream of MEKK1 in ER
activation was
examined. Since some published studies (22) suggested that MEKK1 could
also activate MEK in addition to JNKKs, the involvement of MEK and
JNKK1 in MEKK1-induced ER
activation was investigated. As shown in
Fig. 4A
, coexpression of a dominant
negative JNKK1 blocked ER
activation by MEKK1. On the other hand,
the specific MEK inhibitor PD98059 did little to affect ER
activation by MEKK1 (Fig. 4B
), although, as expected, it inhibited the
ERK activation by RAF (Fig. 4C
). These data suggest that MEKK1
activation of ER
is mediated through JNKK instead of MEK.

View larger version (33K):
[in this window]
[in a new window]
|
Figure 4. Blockage of MEKK1-Mediated ER Activation by
Dominant Negative JNKK1 but Not by a MEK Inhibitor
A, Ishikawa cells were transfected with 0.5 µg EREe1bCAT, 0.5 µg
pLENßgal, 0.1 µg pLEN-hER , and, as indicated, with or without
0.2 µg SR MEKK1(CT) or SR HAJNKK1(AL), which encodes dominant
negative JNKK1 (DN-JNKK). The total amount of DNA used in transfections
was equalized with SR 3. Transfected cells were treated with
10-8 M 17ß-estradiol and CAT activity
was determined. B, Cells were transfected with 0.5 µg EREe1bCAT, 0.5
µg pLENßgal, 0.1 µg pLEN-hER , and either 0.2 µg SR 3 or
0.2 µg SR MEKK1(CT). Transfected cells were treated with or without
10-8 M 17ß-estradiol (E2)
and indicated concentrations of PD98059. PD98059 was dissolved in
dimethylsulfoxide (DMSO), and the absolute amount of DMSO added to all
samples was balanced. CAT activity was determined. C, Cells were
transfected with 0.2 µg SR 3 or SR RAF(BxB) and with or without
0.5 µg HA-ERK2. Transfected cells were treated with indicated
concentrations of PD98059. HA-ERK2 was immunoprecipitated from cell
lysates using anti-HA antibody, and in vitro
immunocomplex kinase assays were performed using MBP (3 µg) as
substrate (top panel). The level of HA-ERK2 expression
was determined by Western blotting using the same anti-HA antibody
(bottom panel). P-MBP, Phosphorylated MBP. Duplicated
samples were analyzed and shown for both assays.
|
|
To assess the involvement of different MAPKs in ER
activation by
MEKK1, the effects of MEKK1 on different MAPKs, JNK1, ERK2, and p38
were first examined. These proteins were expressed in Ishikawa
cells and JNK, ERK, and p38 activities were determined by in
vitro kinase assay using appropriate substrates. In agreement with
previous findings, MEKK1 activated JNK1 (Fig. 5A
). In contrast to other studies which
reported that MEKK1 activated ERK but not p38 (23), we found that MEKK1
did not activate ERK (Fig. 5B
) but significantly increased the activity
of p38 (Fig. 5C
) in Ishikawa cells. As shown in Fig. 4C
, ERK was,
however, effectively activated by RAF, thus indicating that the lack of
effect of MEKK1 on ERK activity was not artifactual. The capacity of
MEKK1 to activate JNK1 and p38 suggests that both kinases may mediate
the effect of MEKK1 on ER
activation.

View larger version (27K):
[in this window]
[in a new window]
|
Figure 5. Activation of JNK and p38, but Not ERK, by MEKK1 in
Ishikawa Cells
A, Ishikawa cells were transfected with 0.5 µg HA-JNK1 and 0.2
µg of either SR MEKK1(CT) or SR 3. HA-JNK1 was immunoprecipitated
from the cell lysates using anti-HA antibody, and in
vitro kinase assays were performed using GST-c-Jun (3 µg) as
substrate (top panel). The level of HA-JNK1 expression
was determined by Western blotting using the same anti-HA antibody
(bottom panel). P-GST-c-Jun, Phosphorylated GST-c-Jun.
B, Cells were transfected with 0.5 µg HA-ERK2 and 0.2 µg of either
SR MEKK1(CT) or SR 3. HA-ERK2 was immunoprecipitated from the cell
lysates using anti-HA antibody, and in vitro
immunocomplex kinase assays were performed using MBP (3 µg) as
substrate (top panel). The level of HA-ERK2 expression
was determined by Western blotting using the same anti-HA antibody
(bottom panel). P-MBP, Phosphorylated MBP. C, Cells were
transfected with 0.2 µg of either SR MEKK1(CT) or SR 3 and with
or without 0.5 µg Flag-p38. Flag-p38 was immunoprecipitated from the
cell lysates using anti-Flag antibody, and in vitro
immunocomplex kinase assays were performed with GST-ATF2 (3 µg) as
substrate (top panel). The level of Flag-p38 expression
was determined by Western blotting using the same anti-Flag antibody
(bottom panel). P-GST-ATF2, Phosphor-ylated
GST-ATF2; duplicated samples were analyzed and shown for both Western
blotting and kinase assays in all panels.
|
|
To determine whether JNK activity was required for ER
activation by
MEKK1, we transfected cells with a dominant negative JNK1 together with
active MEKK1, and the ER
activity was determined. As shown in Fig. 6A
, expression of dominant negative JNK1
decreased the MEKK1-induced ER
activation in a dose-dependent
manner. More interestingly, dominant negative JNK1 also prevented the
estrogen-induced ER activation in the absence of ectopic MEKK1
expression (Fig. 6B
). As expected, dominant negative JNK1 inhibited Jun
activation by MEKK1 (Fig. 6C
). In this study, Jun activation was
determined by measuring the activity of transfected Gal-Jun fusion
protein on a Gal4 reporter, 3x17 mer-Gal-CAT. In the Gal-Jun, Gal4 DNA
binding domain was fused to c-Jun transcriptional activation domain of
which the activity is known to depend on the phosphorylation of
Ser63 and Ser73 by JNKs.
The lack of MEKK1 effect on the Gal-Jun
(Ala63/73) mutant confirmed that the
MEKK1-induced increase in the Gal4 reporter activity accurately
measured MEKK1 activation of JNK1. The dominant negative JNK1 did not
affect the activation of endogenous AP1 by RAF (Fig. 6D
), a process
that is mediated through ERK pathway. Thus, dominant negative JNK1
specifically targeted the JNK pathway. These findings demonstrate that
JNK1 activity is necessary for both MEKK1-induced and
17ß-estradiol-induced ER
activation.

View larger version (19K):
[in this window]
[in a new window]
|
Figure 6. Inhibition of MEKK1- and Estrogen-Induced ER
Activation by Dominant Negative JNK1
A, Inhibition of MEKK1-induced ER activation by dominant negative
JNK1. Ishikawa cells were transfected with 0.5 µg EREe1bCAT, 0.5 µg
pLENßgal, 0.1 µg pLEN-hER , 0.2 µg of either SR 3 or
SR 3MEKK1(CT), and indicated amounts of SR HAJNK1(APF), which
encodes a dominant negative JNK1 (DN-JNK1). Transfected cells were
treated with or without 10-8 M
17ß-estradiol (E2). B, Inhibition of estrogen-induced
ER activation by DN-JNK1 in the absence of ectopic MEKK1 expression.
As in panel A except that cells were not transfected with
SR 3MEKK1(CT) DNA. C, Inhibition of MEKK1-induced c-Jun activation by
DN-JNK1. Cells were transfected with 0.2 µg 3x17 mer-Gal-CAT, 0.5
µg pLENßgal, 0 .1 µg of pGal-Jun(1223) or
pGal-Jun(1223)(Ala63/73), 0.1 µg of SR 3 or
SR MEKK1(CT), and indicated amounts of SR HAJNK1(APF). D, Lack of
inhibition of RAF-induced activation of endogenous AP1 by DN-JNK1. The
cells were transfected with 0.2 µg AP-1-CAT, 0.5 µg pLENßgal, 0.2
µg of SR 3 or SR RAF(BxB), and indicated amounts of
SR HAJNK1(APF). CAT activity was assayed and normalized with ß-gal
activity in all panels.
|
|
We next examined the role of p38 in ER
activation. In these
experiments, Ishikawa cells transfected with active MEKK1 were treated
with p38 inhibitor SB203580. As shown in Fig. 7
, SB203580 inhibited MEKK1-induced ER
activation in a dose-dependent manner (Fig. 7A
) and partially inhibited
the estrogen-induced activation in the absence of ectopic MEKK1
expression (Fig. 7B
), suggesting that p38 is also involved in the ER
activation. As expected, SB203580 inhibited MEKK1-induced p38
activation in a dose-dependent manner (Fig. 7C
) but had no effect on
MEKK1-induced activation of endogenous AP1 (Fig. 7D
), a process that is
mainly mediated through JNK pathways. The data demonstrate that the
effect of the inhibitor on MEKK1 activation of the ER was indeed due to
the specific repression of p38 and that the inhibitor did not affect
transcription in a nonspecific manner in the cells. These findings,
coupled with those presented above, implicate both JNK1 and p38 in the
activation of ER
by MEKK1 and estrogen.

View larger version (26K):
[in this window]
[in a new window]
|
Figure 7. Attenuation of MEKK1- and Estrogen-Induced ER
Activation by a p38 Inhibitor, SB203580
A, Effect of SB203580 on MEKK1-induced ER activation. Ishikawa cells
were transfected with 0.5 µg EREe1bCAT, 0.5 µg pLENßgal, 0.1 µg
pLEN-hER , and 0.2 µg of either SR 3 or SR MEKK1(CT).
Transfected cells were treated with or without 10-8
M 17ß-estradiol (E2) and indicated
concentrations of SB203580. SB203580 was dissolved in DMSO, and the
absolute amount of DMSO added to all samples was balanced. CAT activity
was determined. B, Effect of SB203580 on estrogen-induced ER
activation in the absence of ectopic MEKK1 expression. As in panel A
except that cells were not transfected with SR MEKK1(CT). C,
Inhibition of p38 activity by SB203580. Cells were transfected with 0.2
µg of either SR 3 or SR MEKK1(CT) and with or without 0.5 µg
Flag-p38. Transfected cells were treated with indicated concentrations
of SB203580. Flag-p38 was immunoprecipitated with anti-Flag antibody,
and in vitro immunocomplex kinase assays were performed
using GST-ATF2 (3 µg) as substrates (top panel). The
level of Flag-p38 expression was determined by Western blotting using
the same anti-Flag antibody (bottom panel). Duplicated
samples were analyzed and shown for both assays. P-GST-ATF2,
Phosphorylated GST-ATF2. D, Effect of p38 inhibitor on MEKK1-induced
activation of endogenous AP1. Cells were transfected with 0.2 µg
AP-1-CAT, 0.5 µg pLENßgal, and 0.2 µg of SR MEKK1(CT) or
SR 3. Transfected cells were treated with indicated concentration of
SB203580, harvested, and assayed for CAT activity.
|
|
p38, but Not JNK1, Phosphorylates ER
ER
contains five known phosphorylation sites, some of which are
Ser-Pro motifs that are part of the consensus sequence for
phosphorylation by MAPKs. To test the requirement for each of these
sites for MEKK1-induced ER
activation, we transfected into Ishikawa
cells ER
mutants in which one or two of the known phosphorylation
sites were changed to alanines together with active MEKK1, and reporter
activity was determined. Although a difference in fold increase was
observed, all of the ER
mutants were substantially activated by
MEKK1 (Fig. 8
). This finding indicates
that MEKK1 activation either does not depend on phosphorylation of the
receptor at any of the known phosphorylation sites or is mediated
through redundant receptor phosphorylation of these sites.
Although mutation of the known ER
phosphorylation sites did not
eliminate ER
activation by MEKK1, it is possible that p38 and/or JNK
phosphorylates ER
at a yet unidentified site. To determine whether
p38 phosphorylates ER
, we transfected Flag-tagged p38 into
Ishikawa cells with or without active MEKK1. p38 was then
immunoprecipitated from the cell extracts, and in vitro
immunocomplex kinase assays were performed using full-length
biologically active human ER
protein as a substrate. As shown
in Fig. 9A
, ER
was phosphorylated by
p38 immunocomplex prepared from cells both containing and lacking
active MEKK1. Cotransfection of active MEKK1, however, increased ER
phosphorylation about 3-fold, an amount that correlates well with fold
increase in ER
transcriptional activity that is typically induced by
MEKK1. No phosphorylation of the ER
was detected in the
immunoprecipitates prepared from the control vector-transfected cells,
suggesting that the kinase that phosphorylated ER
in the
immunoprecipitates is indeed Flag-p38. For comparative purposes, we
also examined the phosphorylation of GST-ATF2 by p38 (Fig. 9B
). Taking
into consideration the fact that the mol wt of ER
is more than twice
that of GST-ATF2 and that the amount of ER
used in the kinase assays
was one-sixth that of GST-ATF2, p38 phosphorylated ER
at least
20-fold better than GST-ATF2 (Fig. 9B
). Therefore, ER
is an
excellent substrate for p38.

View larger version (30K):
[in this window]
[in a new window]
|
Figure 9. Phosphorylation of Purified ER Protein by p38
A, Ishikawa cells were transfected with 0.2 µg of either
SR MEKK1(CT) or SR 3 and where indicated, 0.5 µg Flag-p38.
Flag-p38 was immunoprecipitated with anti-Flag antibody, and in
vitro immunocomplex kinase assays were performed using
recombinant human ER protein (0.5 µg) as substrates (top
panel). The level of Flag-p38 expression was determined by
Western blotting using the same anti-Flag antibody (bottom
panel). P-ER, Phosphorylated ER. B, Cells were transfected with
0.5 µg Flag-p38 and 0.2 µg of either SR MEKK1(CT) or SR 3.
Flag-p38 was immunoprecipitated, and in vitro
immunocomplex kinase assays were performed using either recombinant
ER protein (0.5 µg) or GST-ATF2 (3 µg) as substrates (top
panel). The level of Flag-p38 expression was determined by
Western blotting using the same anti-Flag antibody (bottom
panel). P-GST-ATF2, Phosphorylated GST-ATF2. C, Cells were
transfected with or without 0.5 µg HA-JNK1 and 0.2 µg of either
SR MEKK1(CT) or SR 3. HA-JNK1 was immunoprecipitated with anti-HA
antibody, and in vitro immunocomplex kinase assays were
performed using either recombinant human ER protein (0.5 µg),
GST-c-Jun (3 µg), or both as substrates (top panel).
The level of HA-JNK1 expression was determined by Western blotting
using the same anti-HA antibody (bottom panel).
P-GST-c-Jun, phosphorylated GST-c-Jun; duplicated samples were analyzed
and shown for both assays in all panels.
|
|
The capacity of JNK1 to phosphorylate ER
was then determined by the
same protocol used in the p38 studies described above. In contrast to
p38, however, hemagglutinin (HA)-tagged JNK1 did not detectably
phosphorylate ER
regardless of whether or not active MEKK1 was
cotransfected (Fig. 9C
). As shown in Fig. 9C
, ER
was basally
phosphorylated in immunoprecipitates lacking HA-JNK1, and the presence
of MEKK1-activated HA-JNK1 in immunoprecipitates did not increase the
ER
phosphorylation above this basal level. In contrast,
MEKK1-activated HA-JNK1 efficiently phosphorylated GST-c-Jun.
MEKK1-activated HA-JNK1 also phosphorylated GST-c-Jun in assays in
which ER
protein was added to the reaction mixture, eliminating the
possibility that the lack of ER
phosphorylation was due to any
inhibition of activated JNK1 activity by buffer components used to
dissolve ER
. The basal level of ER
phosphorylation detected in
these kinase assays presumably reflects the presence of a
contaminating kinase in the immunoprecipitates.
These studies suggest that JNK and p38 may have different roles in
ER
activation.
MEKK1 Activates ER
in Endometrioid Ovarian Cancer Cells
To determine whether the ER
activation by MEKK1 is limited to
endometrial cancer cells, ER
was transfected into epithelial ovarian
cancer cells containing no endogenous ER
, and its activation by
MEKK1 was examined. As determined by ER reporter assay, active MEKK1
increased ER
activity in the endometrioid ovarian cancer cell line,
MDAH 2774 (Fig. 10A
). The activation
was inhibited by ICI 182,780, and neither MEKK2 nor RAF increased the
ER
activity. On the other hand, none of these kinases, even at high
doses, activated the ER
in the serous ovarian cancer cell, OV1063
(Fig. 10B
). These data suggest that ER
activation by MEKK1 may
be restricted to endometrial cancer and endometrioid ovarian cancer
cells, which are morphologically and characteristically
indistinguishable.

View larger version (26K):
[in this window]
[in a new window]
|
Figure 10. Activation of ER by MEKK1 in Endometrioid
Ovarian Cancer Cells
A, MDAH-2774 endometrioid ovarian cancer cells were transfected with
0.5 µg EREe1bCAT, 0.5 µg pLENßgal, 0.1 µg pLEN-hER , and 0.15
µg of either SR MEKK1(CT), SR HAMEKK2(CT), SR RAF(BxB), or
SR 3. Transfected cells were treated with vesicle (-hormone),
10-9 M 17ß-estradiol (E2)
or 10-9 M 17ß-estradiol plus
10-7 M ICI 182,780 (E2 + ICI)
as indicated. B, OV1063 serous ovarian cancer cells were transfected
with 0.5 µg EREe1bCAT, 0.5 µg pLENßgal, 0.1 µg pLEN-hER , and
indicated amounts of SR MEKK1(CT), SR HAMEKK2(CT), SR RAF(BxB),
or SR 3. Transfected cells were treated with 10-9
M 17ß-estradiol; cells were harvested and assayed
for CAT activity.
|
|
MEKK1 Affects the Agonistic as Well as Antagonistic Activity of
4-Hydroxytamoxifen
ER
is the major ER subtype in the uterus, and tamoxifen is
known to act as an ER agonist in the development of endometrial tumors.
Thus, the effect of MEKK1 on the agonistic activity of tamoxifen was
examined in Ishikawa cells. We found that in the absence of active
MEKK1, 4-hydroxytamoxifen only slightly activated ER
(Fig. 11
) and thus is a poor agonist.
Expression of active MEKK1 resulted in a significant increase in
4-hydroxytamofen-induced ER
activity, the level of which was
comparable to that of cells stimulated with 10-8
M 17ß-estradiol. These findings show that MEKK1
activation allows 4-hydroxtamoxifen to function as a potent ER
agonist.
To determine the effect of MEKK1 on the antagonistic activity of
4-hydroxytamoxifen, we also examined the effect of 4-hydroxytamoxifen
on ER
activity when added to Ishikawa cells in combination with
17ß-estradiol (Fig. 11
). In cells not expressing active MEKK1,
4-hydroxytamoxifen inhibited the estrogen-induced ER
activation as
efficiently as did ICI 182,780. In contrast, in cells expressing active
MEKK1, 4-hydroxytamoxifen did not inhibit the estrogen-induced ER
activation, and in fact, slightly enhanced the activation. These
results demonstrate that 4-hydroxytamoxifen acts as an ER antagonist in
the absence of MEKK1 and an agonist in the presence of MEKK1. ICI
182,780, on the other hand, ablated ER
activation by 17ß-estradiol
and thus functions as an ER antagonist irrespective of whether or not
active MEKK1 is expressed.
 |
DISCUSSION
|
---|
The results of our study demonstrate that MEKK1, but not MEKK2 or
RAF, activated ER genes in endometrial cancer cells. The activation was
observed using both simple or complex promoter-based reporters.
MEKK1- induced activation was inhibited by the estrogen antagonist ICI
182,780 and required cotransfection of the ER
expression plasmid,
and thus is mediated through ER
. Since MEKK1 did not enhance the
level of ER
expression, it must increase the reporter activity by
enhancing the specific transcriptional activity of ER
. Although
MEKK1 consistently enhanced ER
activity in cells treated with
different concentrations of 17ß-estradiol, its effects on the ER
in the absence of ligands were variable. Thus, more studies are
required to determine whether MEKK1 participates in the
ligand-independent activation of ER
.
Our data in endometrial cancer cells show that MEKK1 activated both
JNK1 and p38, and that ER
activation by MEKK1 was mediated through
JNKK-JNK/p38 pathways. These results differ from those of previous
studies which implicate the RAF-ERK pathway in ER
activation in Hela
(19) and COS (18) cells. In these studies, the ER activation resulted
from ERK-mediated phosphorylation of ER
at
Ser118. In our studies, however,
Ala118 ER
mutant was still activated by MEKK1.
In addition, MEKK1 did not activate ERK in our system, and active RAF
did not activate ER
. These results strongly argue against the
involvement of the RAF-ERK pathway in MEKK1-induced ER
activation.
It is important to note that ER
activation by various signals is
both tissue- and promoter specific, and thus our results and others are
not necessarily contradictory. In fact, they raise the interesting
possibility that different cell types use different MAPK pathways to
activate ER
.
Our studies suggest that none of the known phosphorylation sites on
ER
, including Ser118, is absolutely required
for ER
activation by MEKK1. This finding suggests that MEKK1-induced
ER
activation may involve the phosphorylation of ER
at a novel
site. p38 activity was required for ER
activation by MEKK1, and we
found that p38 efficiently phosphorylated ER
in a MEKK1-regulated
manner. p38 phosphorylated ER
to a greater extent than it
phosphorylated GST-ATF2, a physiological substrate for p38; thus, ER
is an excellent substrate for p38. Although JNK activity was also
needed for MEKK1-induced ER
activation, it did not detectably
phosphorylate ER
. Overall, these data suggest that ER
activation
by MEKK1 is mediated through two independently acting downstream
kinases: p38, which directly phosphorylates ER
, and JNK1,
which indirectly promotes ER
activation, perhaps by
phosphorylating proteins interacting with ER
.
Our previous studies on the progesterone receptor (PR)
showed that PR-A and PR-B are differentially activated by MEKK1 and
MEKK2 in Hela cells (24). However, in contrast to the findings in the
current study, PR activation by MEKKs was independent of JNK and p38.
In the case of glucocorticoid receptor, JNK activation repressed
receptor activity, and the repression was relieved by mutation of JNK
sites (25). During the preparation of this manuscript, it was reported
that reporter genes for androgen receptors were activated by MEKK1 in
prostate and breast cancer cells (26). However, in this instance, it
was not clear whether the observed activation resulted from increases
in the expression level or the transcriptional capacity of the
receptor. Moreover, the involvement of JNK and p38 in MEKK1-induced
androgen receptor activation was not examined. We believe our data are
the first to demonstrate that JNK and p38 signaling pathways activate
steroid receptors.
As mentioned in the Introduction, the
uterus exemplifies a system in which both steroid and nonsteroid
signals impinge on the ER in a physiologically relevant manner and
tamoxifen stimulates tumorigenesis. ER
activation by MEKK1 and the
consequent increase in the agonistic activity of tamoxifen compounds
suggest that MEKK1-JNK/p38 may be involved in mediating the stimulatory
effect of estrogen and tamoxifen in tumorigenesis of endometrial
epithelium. The MEKK1-induced activation of ER
transfected into MDAH
2774 cells suggests that MEKK1 may also play a similar positive role in
the formation of endometrioid ovarian cancers, which are
morphologically and characteristically indistinguishable from
endometrial cancers and may have a similar sensitivity to estrogen and
tamoxifen. Although some studies have implicated MEKK1 in apoptosis
(27), a positive role for MEKK1-JNK pathways in tumorigenesis has been
suggested by studies showing that cellular transformation by oncogenes
such as Met (28), Abl (29) and certain mutant EGF receptors (30)
depends on JNK activity and that the genetic deletion of MEKK1 from
mice impaired the survival of murine embryonic fibroblasts to stress
signals (23).
To our knowledge, our data showing that MEKK1 abrogates the
antagonistic activity of 4-hydroxytamoxifen is the first
demonstration of such an effect by an active kinase. Targeting the
MEKK1-JNK/p38 pathway, therefore, represents a potential means of
eliminating the undesired stimulatory effects of tamoxifen in
endometrial tumorigenesis.
 |
MATERIALS AND METHODS
|
---|
Materials
Tissue culture reagents were obtained from Life Technologies, Inc. (Gaithersburg, MD).
[3H]Chloramphenicol was from NEN Life Science Products (Boston, MA), and N-butyryl Coenzyme
A from Pharmacia Biotech (Piscataway, NJ).
17ß-Estradiol, 4-hydroxytamoxifen, myelin basic protein (MBP), and M2
antibody were from Sigma (St. Louis, MO). PD98059 and
SB203580 were from Calbiochem (La Jolla, CA). Purified
hER
protein was from Affinity BioReagents, Inc.
(Golden, CO). GST-ATF2 and GST-c-Jun proteins were from New England Biolabs, Inc. (Beverly, MA). The ECL reagents for
immunoblotting were from Amersham Pharmacia Biotech Inc.
(Piscataway, NJ). Antibody for ER
(F-10) was from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). 12CA5 and protease
inhibitor cocktail tablets were from Roche Molecular Biochemicals (Indianapolis, IN). ICI 182,780 was from Tocris
(Baldwin, MO). All other reagents were reagent grade.
Plasmids
The pLEN-hER
, EREe1bCAT, and EREtkCAT were kindly provided by
Dr. Carolyn L. Smith (31). pLENßgal (24), pGal-ATF2 (32), HA-JNK1
(32), HA-ERK2 (32), Flag-p38 (32), AP-1-CAT (33), pGal-Jun(1223)
(32), pGal-Jun(1223)(Ala63/73) (32), and 3x17
mer-Gal-CAT (34) have been described in previous studies. Dominant
negative MEKK2 is an unpublished construct (B. Su, unpublished).
Constitutively active MEKK1 [SR
MEKK1(CT)] (35), MEKK2
[SR
HAMEKK2(CT)] (36), RAF1 [SR
RAF(BxB)] (37), Rac1 (37) as
well as dominant negative JNK1 [SR
HAJNK1(APF)] (38), MEKK1 (35),
JNKK1 [SR
HAJNKK1(AL)] (36), and full-length MEKK1
(SR
51p1) (39) are all in the SR
3 vector and
have also been described previously.
The receptor phosphorylation site mutants in pCMV5 were kindly provided
by Dr. Benita Katzenellenbogan (40). Due to our unpublished
observation that the cytomegalovirus (CMV) promoter was strongly
activated by constitutively active MEKK1, which interferes with our
transcriptional assays, all mutants were subcloned into the same pLEN
vector used to express the wild-type receptor as well as
ß-galactosidase, the internal standard for normalization of the
reporter activity in all of our transcription assays. The
Ala537 mutant was removed from pCMV5 by
BamHI and ligated into the BamHI site in pLEN.
pCMV5 expressing the remainder of the mutants was first digested with
EcoRI at the 5'-end of the mutant ER cDNA and a
BamHI-EcoRI linker was then ligated to it. The
plasmids were further cut by BamHI at the 3'-end, and the
mutant cDNAs were ligated into the BamHI site of the pLEN
vector.
Transfections
Ishikawa cells were grown in DMEM containing 10% FBS. One day
after plating, cells were transfected by a lipofectamine-mediated
transfection procedure following the protocol from Life Technologies, Inc. In brief, the medium was removed, and phenol
red-free DMEM was added to the cells. The DNA-lipofectamine complexes
were prepared and added dropwise to the cells. After 5 h
incubation, cells were washed with HBSS, and phenol red-free DMEM
containing 1% charcoal-stripped FBS was added to the cells. On the
following day, hormones and inhibitors were added to the cells. After
24 h, cells were harvested and assayed for CAT and
ß-galactosidase (ß-gal) activity as indicated below. For in
vitro kinase assays and Western blots, cells were treated on the
third day after transfection with hormone or kinase inhibitors for 30
min and lysed.
Transcriptional Assays
The transfected cells were harvested by scraping into TEN buffer
(40 mM Tris, 1 mM EDTA, 150 mM
NaCl, pH 8.0), collected by centrifugation, resuspended in 0.25
M Tris, pH 7.5, and lysed by freeze-thawing. CAT activity
(41, 42) and ß-gal activity (41) were assayed as previously
described. CAT activity was normalized to ß-gal activity. Duplicate
samples were analyzed for each data point.
In Vitro Immunocomplex Kinase Assays
Transfected cells were washed with ice-cold PBS and lysed in
buffer containing 20 mM Tris (pH. 7.6), 250 mM
NaCl, 3 mM EDTA, 3 mM EGTA, 5 mM
ß-glycerophosphate, 100 µM
Na3VO4, 0.5% NP-40, and
protease inhibitor cocktail (1 tablet/10 ml) for JNK1 or ERK2 kinase
assays. For p38 kinase assays, the transfected cells were lysed in
buffer containing 10 mM HEPES (pH 7.6), 250 mM
NaCl, 3 mM EDTA, 100 mM
Na3VO4, 1% Triton X-100,
and protease cocktail (1 tablet/10 ml). After centrifugation, half of
the supernatant was immunoprecipitated with 12CA5 antibody for HA-ERK2
and HA-JNK1 or M2 antibody for Flag-p38. Kinase reactions were
performed at 30 C in 20 µl buffer containing 20 mM HEPES
(pH 7.6), 10 mM PNPP, 20 mM
MgCl2, 2 mM EDTA, 2 mM
EGTA, 100 µM
Na3VO4, 10 µM
ATP, 10 µCi
-32P-ATP with the appropriate
substrate. For MBP, GST-c-Jun, and GST-ATF2, 3 µg were used and, for
the purified ER
protein, 0.5 µg was used. Reactions were
terminated by adding 2x SDS-PAGE sample buffer, analyzed by SDS-PAGE,
and visualized by autoradiography. For each kinase assay, duplicate
samples were analyzed.
Immunoblotting Analysis
To determine ER
expression, transfected cells were
washed with PBS and lysed by adding 0.5 ml hot 2x SDS-PAGE sample
buffer directly to the plate. The cells were scraped into 1.5-ml
microcentrifuge tubes, heated at 100 C for 10 min, and spun for 10 min
at room temperature in a microcentrifuge set at maximum speed.
Supernatants (50 µl) was separated on a 7.5% SDS gel.
To determine the expression of HA-ERK2, HA-JNK1, and Flag-p38, half of
the cell lysate prepared for kinase assays was mixed with one sixth of
6x SDS-PAGE sample buffer, heated for 10 min at 100 C, and separated
on a 10% SDS gel.
After separation on SDS-PAGE, all samples were transferred to
nitrocellulose membrane, probed with the corresponding antibodies, and
visualized using an ECL kit following the instructions of the
manufacture. For each Western blot, duplicate samples were
analyzed.
 |
ACKNOWLEDGMENTS
|
---|
The authors thank Dr. Carolyn L. Smith for the ER expression and
reporter vectors, Dr. Benita S. Katzenellenbogen for phosphorylation
site mutants of the ER
and Drs. Doug Cress, Nancy Olashaw, and
Warren J. Pledger for critical reading of the manuscript.
 |
FOOTNOTES
|
---|
Address requests for reprints to: Wenlong Bai, Department of Pathology, University of South Florida College of Medicine and H. Lee Moffitt Cancer Center, 12901 Bruce B. Downs Boulevard, MDC 11, Tampa, Florida 33612-4799. E-mail: wbai{at}com1.med.usf.edu
This work was supported by NIH Grant R29 CA-79530 to W.B.
Received for publication April 12, 2000.
Revision received August 1, 2000.
Accepted for publication August 7, 2000.
 |
REFERENCES
|
---|
-
Evans RM 1988 The steroid and thyroid hormone receptor
superfamily. Science 240:889895[Medline]
-
Tsai M-J, OMalley BW 1995 Molecular mechanisms of action of
steroid/thyroid receptor superfamily members. Annu Rev Biochem 63:451486[CrossRef][Medline]
-
Kuiper GGJM, Enmark E, Peito-Huikko M, Nilson S, Gutafsson
J-A 1996 Cloning of a novel estrogen receptor expressed in rat prostate
and ovary. Proc Natl Acad Sci USA 93:59255930[Abstract/Free Full Text]
-
Mosselman S, Polman J, Dijkema R 1996 ER ß:
identification and characterization of a novel human estrogen receptor.
FEBS Lett 392:4953[CrossRef][Medline]
-
Tremblay GB, Tremblay A, Copeland NC, Gilbert DJ, Jenkins NA,
Labrie F, Giguere V 1997 Cloning, chromosomal localization and
functional analysis of the murine estrogen receptor ß. Mol Endocrinol 11:353363[Abstract/Free Full Text]
-
Tora L, Whote J, Brou C, Tasset D, Webster N, Scheer E,
Chambon P 1989 The human estrogen receptor has two independent
nonacidic transcriptional activation domains. Cell 59:477487[Medline]
-
Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG,
Stein RB, Pike WJ, McDonnell DP 1994 Human estrogen receptor
transactivation capacity is determined by both cellular and promoter
context and mediated by two functionally distinct intramolecular
regions. Mol Endocrinol 8:2130[Abstract]
-
Kuiper GGJM, Carlsson B, Grandien K, Enmark E, Haggblad J,
Nilsson S, Gutafsson J 1997 Comparison of the ligand binding
specificity and transcript tissue distribution of estrogen
receptor
and ß. Mol Endocrinol 138:863870
-
Saunders PTK, Maguire SM, Gaughan J, Miller MR 1997 Expression of estrogen receptor beta (ER ß) in multiple rat
tissues visualized by immunohistochemistry. J Endocrinol 154:R13R16
-
Bai W, Weigel NL 1995 Phosphorylation and steroid hormone
action. Vitam Horm 51:289313[Medline]
-
Ignar-Trowbridge DM, Nelson KG, Bidwell MC, Curtis SW,
Washburn TF, Machlachlan JA, Korach KS 1992 Coupling of dual signaling
pathways: epidermal growth factor action involves the estrogen
receptor. Proc Natl Acad Sci USA 89:46584662[Abstract]
-
Kazenellenbogen BS, Norman MJ 1990 Multihormonal regulation of
the progesterone receptor in MCF-7 human breast cancer cells:
interrelationships among insulin/ insulin-like growth factor-I,
serum, and estrogen. Endocrinology 126:891898[Abstract]
-
Aronica SM, Kazenellenbogen BS 1993 Stimulation of estrogen
receptor-mediated transcription and alteration in the phosphorylation
state of the rat uterine estrogen receptor by estrogen, cyclic
adenosine monophosphate, and insulin-like growth factor-1. Mol
Endocrinol 7:743752[Abstract]
-
Sumida C, Pasqualini JR 1990 Stimulation of progesterone
receptors by phorbol ester and cyclic AMP in fetal uterine cells in
culture. Mol Cell Endocrinol 69:20715[CrossRef][Medline]
-
Sumida C, Pasqualini JR 1989 Antiestrogens antagonize the
stimulatory effect of epidermal growth factor on the induction of
progesterone receptor in fetal uterine cells in culture. Endocrinology 124:5917[Abstract]
-
Nelson KG, Takahashi T, Bossert NL, Walmer DK McLachlan JA 1991 Epidermal growth factor replaces estrogen in the stimulation of
female genital-tract growth and differentiation. Proc Natl Acad Sci USA 88:215[Abstract]
-
Curtis SW, Washburn T, Sewall C, DiAugustine R, Lindzey J,
Couse JF Korach KS 1996 Physiological coupling of growth factor and
steroid receptor signaling pathways: estrogen receptor knockout mice
lack estrogen-like response to epidermal growth factor. Proc Natl Acad
Sci USA 93:1262630[Abstract/Free Full Text]
-
Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H,
Masushige H, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P 1995 Activation of the estrogen receptor through phosphorylation by
mitogen-activated protein kinase. Science 270:14911494[Abstract]
-
Bunone G, Briand P, Miksicek RJ, Picard D 1996 Activation of
the unliganded estrogen receptor by EGF involves the MAP kinase pathway
and direct phosphor-ylation. EMBO J 15:21742183[Abstract]
-
Nishida M, Kasahara K, Oki A, Satoh T, Arai Y, Kubo T 1996 Establishment of eighteen clones of Ishikawa cells. Hum Cell 9:109116[Medline]
-
Nawaz Z, Lonard DM, Dennis AP, Smith CL, OMalley BW 1999 Proteasome-dependent degradation of the human estrogen receptor. Proc
Natl Acad Sci USA 96:18581862[Abstract/Free Full Text]
-
Lange-Carter CA, Pleiman CM, Gardner AM, Blumer KJ, Johnson GL 1993 A divergence in the MAP kinase regulatory network defined by MEK
kinase and Raf. Science 260:315319[Medline]
-
Yujiri T, Sather S, Fanger GR, Johnson GL 1998 Role of MEKK1
in cell survival and activation of JNK1 and ERK pathways by targeted
gene disruption. Science 282:19111914[Abstract/Free Full Text]
-
Bai W, Bingman III WE, Yang J, Edwards DP, Su B, Weigel NL,
Differential activation of PR-A and PR-B by MEKKs. Program of the
80th Annual Meeting of The Endocrine Society. New
Orleans, LA, 1998 (Abstract OR145)
-
Krstic MD, Rogatsky I, Yamamoto KR, Garabedian MJ 1997 Mitogen-activated and cyclin-dependent protein kinases selectively and
differentially modulate transcriptional enhancement by the
glucocorticoid receptor. Mol Cell Biol 17:39473954[Abstract]
-
Abreu-Martin MT, Chari TA, Palladino A, Craft NA, Sawyers CL 1999 Mitogen-activated protein kinase kinase kinase 1 activates
androgen receptor-dependent transcription and apoptosis in prostate
cancer. Mol Cell Biol 19:51435154[Abstract/Free Full Text]
-
Widmann C, Johnson NL, Gardner AM, Smith RJ, Johnson GL 1997 Potentiation of apoptosis by low dose stress stimuli in cells
expressing activated MEK kinase 1. Oncogene15:24392447
-
Rodrigues GA, Park M, Schlessinger J 1997 Activation of the
JNK pathways is essential for transformation by the Met oncogene. EMBO
J 16:26342645[Abstract/Free Full Text]
-
Raitano AB, Halpern JR, Hambuch TM, Sawyers CL 1995 The
Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for
transformation. Proc Natl Acad Sci USA 92:1174650[Abstract]
-
Antonyak MA, Moscatello DK, Wong AJ 1998 Constitutive
activation of c-Jun N-terminal kinase by a mutant epidermal growth
factor receptor. J Biol Chem 273:28172822[Abstract/Free Full Text]
-
Smith CL, Conneely OM, OMalley BM 1993 Modulation of the
ligand-independent activation of the human estrogen receptor by hormone
and antihormone. Proc Natl Acad Sci USA 90:61206124[Abstract]
-
Yang J, New L, Jiang Y, Han J, Su B 1998 Molecular cloning and
characterization of a human protein kinase that specifically activates
c-Jun N-terminal kinase. Gene 212:95102[CrossRef][Medline]
-
Aronheim A, Engelberg D, Li N, al-Alawi N, Schlessinger J,
Karin M 1994 Membrane target of nucleotide exchange factor Sos is
sufficient for activating the Ras signaling pathway. Cell 78:949961[Medline]
-
Onate SA, Tsai SY, Tsai M-J, OMalley BW 1995 Sequence and
Characterization of a coactivator for the steroid hormone receptor
superfamily. Science 270:13541357[Abstract]
-
Minden A, Lin A, Mcmahon M, Lange-Carter C, Derjard B, Davis
RJ, Johnson GL, Karin M 1994 Differential activation of ERK and JNK
mitogen activated protein kinases by Ras-1 and MEKK. Science 266:17191723[Medline]
-
Cheng J, Yang J, Xia Y, Karin M, Su B 2000 Synergistic
interaction of MEKK2, JNKK2, JNK1 results in efficient, specific JNK1
activation. Mol Cell Biol 20:23342342[Abstract/Free Full Text]
-
Minden A, Lin A, Claret F-X, Abo A, Karin M 1995 Selective
activation of the JNK signaling cascade and c-Jun transcriptional
activity by the small GTPase Rac and Cdc42Hs. Cell 81:11471157[Medline]
-
Kallunki T, Su B, Tsigelny I, Sluss HK, Derijard B, Moore G,
Davis R, Karin M 1994 JNK2 contains a specificity-determining region
responsible for efficient c-Jun binding and phosphorylation. Genes Dev 8:29963007[Abstract]
-
Xia Y, Wu Z, Su B, Murray B, Karin M 1998 JNKK1 organizes a
MAP kinase module through specific and sequential interactions with
upstream and downstream components mediated by its amino-terminal
extension. Genes Dev 12:33693381[Abstract/Free Full Text]
-
Lee Goff P, Montano MM, Schodin DJ, Katzenellenbogen BS 1994 Phosphorylation of human estrogen receptor. J Biol Chem 269:44584466[Abstract/Free Full Text]
-
Bai W, Weigel NL 1996 Phosphorylation of Ser
211 in the chicken progesterone receptor
modulates its transcriptional activity J Biol Chem 271:1280112806[Abstract/Free Full Text]
-
Brian S, Sheen J 1988 A simple phase-extraction assay for
chloramphenicol acetyltransferase activity. Gene 67:271277[CrossRef][Medline]